1
Thor(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.Quadri et al. BMC Cancer (2017) 17:Page 2 ofBackground While advances in the understanding of cancer biology, sc
1
Cts that pancreatic cancer will rank second of all cancer-related mortalities by the year 2030 [1, 2]. Neither current chemotherapy nor molecular therapy provides patients with an extension of survival measured by more than a few months, or the hope for sustained tumor regressions. Even in the minority of patients who are able to undergo surgical resection, median overall survival remains poor [3]
1
Ells stained [24, 25]. CNKSR1 expression was evaluated based on intensity semiquantitatively on a four-tier scale (0 = negative, 1 = weak/background, 2 = moderate/positive, 3 = strongly positive). CNKSRshows minimal expression in lymphoid tissues according to RNA-Seq data and immunohistochemical staining from the Human Protein Atlas (Human Protein Atlas available from www.proteinatlas.org) [26]. S
1
Py, Black or Hispanic race/ethnicityQuadri et al. BMC Cancer (2017) 17:Page 10 ofFig. 7 Survival stratified by resection and CNKSR1 expression status. a Survival in limited subset of primary tumor biopsy specimens showing low CNKSR1 expression by resection status (p = 0.367). b Survival in patients with high CNKSR1 expression by resection status (p
1
On by age, race, gender, grade, resection status, the TNM variables lymph node status (N0; No regional lymph node metastasis, N1; Regional lymph node metastasis, and NX;Quadri et al. BMC Cancer (2017) 17:Page 3 ofRegional lymph nodes cannot be assessed) and distant metastasis (M0; No distant metastasis, and M1; Distant metastasis), SEER stage (localized, regional, and distant), radiation, and prim
1
Ns were transferred to nitrocellulose and these membranes were incubated with primary antibody for 60 minutes (anti-Gal1 from Research Diagnostics, Flanders, New Jersey, anti-beta actin from Sigma, St. Louis, Missouri). After washing and incubation with secondary antibody (Goat Anti-Mse IgG-HRP, Pierce, Rockford, IL), developing solution was added to the membrane (Supersignal West Femto Substrate,